Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

KaNDy Therapeutics
→
Bayer

Acquisition · Cash + milestone payments · announced Aug 11, 2020

View in network
  1. Announced

    Aug 11, 2020

  2. Closed

    Sep 9, 2020

Economics

Cash + milestone payments()

Pre-deal · pre-deal mark: 2020, year precision · rounding grid ±$100M · Bayer press release — KaNDy Therapeutics acquisition, 2020

$425M upfront; up to $450M in development milestones + triple-digit-million sales milestones

Target

KaNDy Therapeutics

Menopause · Clinical / therapeutic

HQ Stevenage, UK · Founded 2017

Clinical-stage biotech developing NT-814 (elinzanetant) for menopausal vasomotor symptoms

  • Business Wire - Bayer acquisition announcement (August 11, 2020)
  • Business Wire - Bayer completion announcement (September 9, 2020)
  • Bayer.com media release

Acquirer

Bayer

Healthcare

HQ Leverkusen, Germany

Global pharma and life sciences company; leader in women's healthcare and contraception

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Reinforced Bayer's women's healthcare pipeline with NT-814/elinzanetant, a non-hormonal Phase IIb compound for moderate-to-severe menopausal vasomotor symptoms

Evidence ladder

Press only — no primary filingValue disclosed
  1. Secondary (press / IR)

    Business Wire press release (August 11, 2020)

  2. Tertiary (trade / analyst)

    Bayer.com media (September 9, 2020)

Limitations

  • Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
  • $425M upfront; up to $450M in development milestones + triple-digit-million sales milestones
  • Pre-deal valuation sourced from: Bayer press release — KaNDy Therapeutics acquisition, 2020. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Menopause

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
Ogeda SAAstellas PharmaApr 3, 2017same evidence class

Other verified deals by Bayer

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Bayer are already listed above, or none are in the dataset.

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — KaNDy Therapeutics (Menopause). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.